

Hypothyroidism pipeline Research Monitor, 2020- Drugs, Companies, Clinical Trials, R&D pipeline updates, status and outlook

<https://marketpublishers.com/r/H67F324422EFEN.html>

Date: July 2020

Pages: 48

Price: US\$ 1,599.00 (Single User License)

ID: H67F324422EFEN

Abstracts

2020 Hypothyroidism PIPELINE HIGHLIGHTS

Hypothyroidism is one of the widely researched conditions during 2020 with 7 companies actively focusing on realizing pipeline's potential. Development of Hypothyroidism medicines is identified as integral to the strategy of the majority of companies operating in the industry.

Global Hypothyroidism market presents promising new product pipeline with NME Projects, pivotal trials, and rapidly phase-advancing therapeutic candidates. Increasing number of companies are assessing the feasibility of developing treatment options for Hypothyroidism.

Good progress is anticipated during 2020 and 2021 with Hypothyroidism pipeline molecules advancing from pre-clinical investigation to completion of advanced Phase clinical trials. Hypothyroidism pipeline continues to expand and progress with novel mechanisms and diverse routes of administration being tested by companies.

Hypothyroidism DRUG DEVELOPMENT PIPELINE OVERVIEW

The "Hypothyroidism pipeline Research Monitor, 2020" report is an analytical research study on the progress achieved by pipeline companies during the year along with its historical development, current status, and outlook.

This Hypothyroidism pipeline review explores high-potential early to late-stage pipeline projects with a continued focus on new insights, accelerated processes, and pipeline progression.

The competitive intelligence report on Hypothyroidism presents detailed insights into therapeutic drug pipeline development, industry news, deals, and analysis across the length and breadth of the Hypothyroidism pipeline. Information on R&D pipeline

updates, results of key clinical trials are also included in the report.

Hypothyroidism DRUG PROFILES

Hypothyroidism development pipeline including projects in early- and late-stage development are detailed in the report. Details of clinical trial data and submissions to regulatory authorities are also provided. For the drug candidates included in the report, the following information is provided-

Current Status of Development including phase advancements, regulatory approvals of phases, acquisitions, licensing and technology transfers, product launches in various markets, and others.

Phase of development

Mechanism of Action

Route of Administration

Companies involved including originator, licensing companies, developer, investors, and others

New molecular entity details

Orphan drug designation and other special status provided by regulators

Hypothyroidism COMPANY PROFILES

Both small size and large size pharmaceutical companies are investing their resources in Hypothyroidism drug development operations. Further, financial institutions are extending support to small pharmaceutical companies, universities, and other researchers for the development of treatment of Hypothyroidism. Partnerships and acquisitions are also increasingly observed in the pipeline.

This research report presents an analysis of 7 Hypothyroidism companies including company overview, key snapshot, contact information, and their strategies on accelerating Hypothyroidism pipeline development. Mid-stage and early portfolios of these companies are analyzed in detail in the report.

Companies analyzed in the report include- Diurnal Group Plc, Eton Pharmaceuticals

Inc, Kashiv BioSciences LLC, Spectrix Therapeutics LLC, Synthonics Inc, Takeda Pharmaceutical Co Ltd, Titan Pharmaceuticals Inc

REASONS TO BUY

The current market conditions are forcing companies and investors worldwide to prioritize their investments and accelerate pipeline candidates only through careful quantitative assessment.

This research work assists decision makers in pharmaceutical companies towards successful pipeline development through critically evaluated pipeline data

Buyers can identify most promising drug candidates for treatment of Hypothyroidism

It allows users to strengthen their pipeline through acquisitions, licensing and collaborations

Users can estimate possible delays in the delivery of pipeline or launch of new products

Stay ahead of competition through understanding their pipeline progression, strategies and outlook

The report details all the pipeline candidates under investigation in various stages of development from Phase I through to Phase III to enable business development managers to understand the impact of new launches.

Optimize your licensing and technology transfer strategies through identification of prospect partners

Contents

1. INTRODUCTION TO HYPOTHYROIDISM

- 1.1 Hypothyroidism- Disease overview
- 1.2 Hypothyroidism- Market Size
- 1.3 Hypothyroidism- Companies Involved

2. HYPOTHYROIDISM PIPELINE SNAPSHOT- 2020

- 2.1 Hypothyroidism Pipeline by Phase
- 2.2 Hypothyroidism Pipeline by Mechanism of Action
- 2.3 Hypothyroidism Pipeline by Route of Administration
- 2.4 Hypothyroidism Pipeline- New Molecular Entities
- 2.5 Hypothyroidism Pipeline- Orphan Drug Designation/ Special Designation

3. HYPOTHYROIDISM DRUG PROFILES

- 3.1 Current Status
- 3.2 Hypothyroidism Drug Snapshot
- 3.3 Hypothyroidism Therapeutic Candidates- Originator/Licensor
- 3.4 Route of Administration
- 3.5 Mechanism of Action
- 3.6 NME
- 4.1 Diurnal Group Plc Hypothyroidism Pipeline Insights and Clinical Trials
- 4.2 Eton Pharmaceuticals Inc Hypothyroidism Pipeline Insights and Clinical Trials
- 4.3 Kashiv BioSciences LLC Hypothyroidism Pipeline Insights and Clinical Trials
- 4.4 Spectrix Therapeutics LLC Hypothyroidism Pipeline Insights and Clinical Trials
- 4.5 Synthomics Inc Hypothyroidism Pipeline Insights and Clinical Trials
- 4.6 Takeda Pharmaceutical Co Ltd Hypothyroidism Pipeline Insights and Clinical Trials
- 4.7 Titan Pharmaceuticals Inc Hypothyroidism Pipeline Insights and Clinical Trials

5. HYPOTHYROIDISM MARKET NEWS AND UPDATES

6. APPENDIX

- 6.1 Sources and Methodology
- 6.2 Contact Information

I would like to order

Product name: Hypothyroidism pipeline Research Monitor, 2020- Drugs, Companies, Clinical Trials, R&D pipeline updates, status and outlook

Product link: <https://marketpublishers.com/r/H67F324422EFEN.html>

Price: US\$ 1,599.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/H67F324422EFEN.html>